A possible mechanism of the nucleus accumbens and ventral pallidum 5-HT1B receptors underlying the antidepressant action of ketamine: A PET study with macaques

Translational Psychiatry

Volumn 4, Issue , 2014, Pages

  Yamanaka, H ^a   Yokoyama, C ^a   Mizuma, H ^a   Kurai, S ^a   Finnema, S J ^b   Halldin, C ^b   Doi, H ^a   Onoe, H ^a  

^a RIKEN   (Japan)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

5 HT1B receptor; 11C AZ10419369; AMPA receptor; Ketamine; Macaque monkey; Nucleus accumbens

Indexed keywords

6 NITRO 7 SULFAMOYLBENZO[F]QUINOXALINE 2,3 DIONE; AMPA RECEPTOR; AZ 10419369 C 11; FENFLURAMINE; KETAMINE; N,N DIMETHYL 2 (2 AMINO 4 CYANOPHENYLTHIO)BENZYLAMINE C 11; RADIOLIGAND; SEROTONIN; SEROTONIN 1B RECEPTOR; SEROTONIN TRANSPORTER; UNCLASSIFIED DRUG; 2,3-DIOXO-6-NITRO-7-SULFAMOYLBENZO(F)QUINOXALINE; AMINO ACID RECEPTOR BLOCKING AGENT; ANTIDEPRESSANT AGENT; CARBON; QUINOXALINE DERIVATIVE; 2,3 DIHYDROXY 6 NITRO 7 SULFAMOYLBENZO(F)QUINOXALINE; 8 (1 PIPERAZINYL) 5 METHYLCHROM 2 EN 4 ONE 2 (4 MORPHOLINOPHENYL)CARBOXAMIDE C 11; AMPA RECEPTOR ANTAGONIST;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIDEPRESSANT ACTIVITY; ARTICLE; BINDING KINETICS; CONTINUOUS INFUSION; CONTROLLED STUDY; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; GLOBUS PALLIDUS; MAJOR DEPRESSION; MALE; NEUROIMAGING; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SCANNER; NUCLEUS ACCUMBENS; POSITRON EMISSION TOMOGRAPHY; RHESUS MONKEY; SEROTONINERGIC SYSTEM; VOXEL BASED MORPHOMETRY; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; FOREBRAIN; MACACA; METABOLISM; BRAIN REGION; DRUG UPTAKE; LATERAL GENICULATE BODY; NEUROTRANSMISSION; OCCIPITAL CORTEX; PET SCANNER; POSTSYNAPTIC POTENTIAL; RADIOACTIVITY; RECEPTOR BINDING; REUNIENS NUCLEUS; SUBSTANTIA NIGRA; UPREGULATION; VENTRAL PALLIDUM;

ANIMALS; ANTIDEPRESSIVE AGENTS; BASAL FOREBRAIN; CARBON RADIOISOTOPES; EXCITATORY AMINO ACID ANTAGONISTS; FENFLURAMINE; KETAMINE; MACACA; MALE; NUCLEUS ACCUMBENS; POSITRON-EMISSION TOMOGRAPHY; QUINOXALINES; RECEPTOR, SEROTONIN, 5-HT1B; RECEPTORS, AMPA; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS;

EID: 84893354108     PISSN: None     EISSN: 21583188     Source Type: Journal    
DOI: 10.1038/tp.2013.112     Document Type: Article

References (48)

1. Giannini AJ, Underwood NA, Condon M. Acute ketamine intoxication treated by haloperidol: A preliminary study. Am J Ther 2000; 7: 389-391.
2. Morgan CJ, Curran HV. Ketamine use: A review. Addiction 2012; 107: 27-38.
3. Peck TE, Hill SA, Williams M. Pharmacology for anaesthesia and intensive care. 3rd edn., Cambridge University Press: Cambridge, 2008.
4. Quibell R, Prommer EE, Mihalyo M, Twycross R, Wilcock A. Ketamine. J Pain Symptom Manage 2011; 41: 640-649.
5. Berman RM, Cappiello A, Anand A, Oren DA, Heninger GR, Charney DS et al. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry 2000; 47: 351-354. (Pubitemid 30109248)
6. Zarate CA Jr, Singh JB, Carlson PJ, Brutsche NE, Ameli R, Luckenbaugh DA et al. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry 2006; 63: 856-864. (Pubitemid 44188478)
7. Autry AE, Adachi M, Nosyreva E, Na ES, Los MF, Cheng PF et al. NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses. Nature 2011; 475: 91-95.
8. Maeng S, Zarate CA Jr, Du J, Schloesser RJ, McCammon J, Chen G et al. Cellular mechanisms underlying the antidepressant effects of ketamine: role of alphaamino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors. Biol Psychiatry 2008; 63: 349-352. (Pubitemid 351146651)
9. Koike H, Iijima M, Chaki S. Involvement of AMPA receptor in both the rapid and sustained antidepressant-like effects of ketamine in animal models of depression. Behav Brain Res 2011; 224: 107-111.
10. Li N, Lee B, Liu RJ, Banasr M, Dwyer JM, Iwata M et al. mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science 2010; 329: 959-964.
11. Mann JJ. Role of the serotonergic system in the pathogenesis of major depression and suicidal behavior. Neuropsychopharmacology 1999; 21(2 Suppl): 99S-105S. (Pubitemid 29396477)
12. Blier P, de Montigny C, Chaput Y. Modifications of the serotonin system by antidepressant treatments: implications for the therapeutic response in major depression. J Clin Psychopharmacol 1987; 7(6 Suppl): 24S-35S. (Pubitemid 18014273)
13. Pytliak M, Vargova V, Mechirova V, Felsoci M. Serotonin receptors -from molecular biology to clinical applications. Physiol Res 2011; 60: 15-25.
14. Ruf BM, Bhagwagar Z. The 5-HT1B receptor: A novel target for the pathophysiology of depression. Curr Drug Targets 2009; 10: 1118-1138.
15. Zhao Y, Sun L. Antidepressants modulate the in vitro inhibitory effects of propofol and ketamine on norepinephrine and serotonin transporter function. J Clin Neurosci 2008; 15: 1264-1269.
16. Nishimura M, Sato K, Okada T, Yoshiya I, Schloss P, Shimada S et al. Ketamine inhibits monoamine transporters expressed in human embryonic kidney 293 cells. Anesthesiology 1998; 88: 768-774. (Pubitemid 28120212)
17. Chatterjee M, Verma R, Ganguly S, Palit G. Neurochemical and molecular characterization of ketamine-induced experimental psychosis model in mice. Neuropharmacology 2012; 63: 1161-1171.
18. Tao R, Auerbach SB. Anesthetics block morphine-induced increases in serotonin release in rat CNS. Synapse 1994; 18: 307-314. (Pubitemid 24357830)
19. Svenningsson P, Chergui K, Rachleff I, Flajolet M, Zhang X, El Yacoubi M et al. Alterations in 5-HT1B receptor function by p11 in depression-like states. Science 2006; 311: 77-80. (Pubitemid 43063061)
20. Murrough JW, Henry S, Hu J, Gallezot JD, Planeta-Wilson B, Neumaier JF et al. Reduced ventral striatal/ventral pallidal serotonin1B receptor binding potential in major depressive disorder. Psychopharmacology 2011; 213: 547-553.
21. Finnema SJ, Varrone A, Hwang TJ, Gulyas B, Pierson ME, Halldin C et al. Fenfluramine-induced serotonin release decreases [11C]AZ10419369 binding to 5-HT1B-receptors in the primate brain. Synapse 2010; 64: 573-577.
22. Finnema SJ, Varrone A, Hwang TJ, Halldin C, Farde L. Confirmation of fenfluramine effect on 5-HT(1B) receptor binding of [11C]AZ10419369 using an equilibrium approach. J Cereb Blood Flow Metab 2012; 32: 685-695.
23. Watakabe A, Komatsu Y, Sadakane O, Shimegi S, Takahata T, Higo N et al. Enriched expression of serotonin 1B and 2A receptor genes in macaque visual cortex and their bidirectional modulatory effects on neuronal responses. Cereb Cortex 2009; 19: 1915-1928.
24. Pierson ME, Andersson J, Nyberg S, McCarthy DJ, Finnema SJ, Varnas K et al. [11C] AZ10419369: A selective 5-HT1B receptor radioligand suitable for positron emission tomography (PET). Characterization in the primate brain. Neuroimage 2008; 41: 1075-1085.
25. Wilson AA, Ginovart N, Schmidt M, Meyer JH, Threlkeld PG, Houle S. Novel Radiotracers for Imaging the Serotonin Transporter by Positron Emission Tomography: Synthesis, Radiosynthesis, and in Vitro and ex Vivo Evaluation of 11CLabeled 2-(Phenylthio)araalkylamines. J Med Chem 2000; 43: 3103-3110. (Pubitemid 30626767)
26. Yokoyama C, Yamanaka H, Onoe K, Kawasaki A, Nagata H, Shirakami K et al. Mapping of serotonin transporters by positron emission tomography with [11C] DASB in conscious common marmosets: comparison with rhesus monkeys. Synapse 2010; 64: 594-601.
27. Logan J, Fowler JS, Volkow ND, Wang GJ, Ding YS, Alexoff DL. Distribution volume ratios without blood sampling from graphical analysis of PET data. J Cereb Blood Flow Metab 1996; 16: 834-840. (Pubitemid 26292051)
28. Ichise M, Liow JS, Lu JQ, Takano A, Model K, Toyama H et al. Linearized reference tissue parametric imaging methods: Application to [11C]DASB positron emission tomography studies of the serotonin transporter in human brain. J Cereb Blood Flow Metab 2003; 23: 1096-1112. (Pubitemid 37082435)
29. Udo de Haes JI, Harada N, Elsinga PH, Maguire RP, Tsukada H. Effect of fenfluramine-induced increases in serotonin release on [18F]MPPF binding: A continuous infusion PET study in conscious monkeys. Synapse 2006; 59: 18-26. (Pubitemid 41706151)
30. Sanacora G, Zarate CA, Krystal JH, Manji HK. Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders. Nat Rev Drug Discov 2008; 7: 426-437. (Pubitemid 351619114)
31. Akinfiresoye L, Tizabi Y. Antidepressant effects of AMPA and ketamine combination: role of hippocampal BDNF, synapsin, and mTOR. Psychopharmacology 2013; 230: 291-298.
32. Traynelis SF, Wollmuth LP, McBain CJ, Menniti FS, Vance KM, Ogden KK et al. Glutamate receptor ion channels: structure, regulation, and function. Pharmacol Rev 2010; 62: 405-496.
33. Lorrain DS, Baccei CS, Bristow LJ, Anderson JJ, Varney MA. Effects of ketamine and N-methyl-D-aspartate on glutamate and dopamine release in the rat prefrontal cortex: modulation by a group II selective metabotropic glutamate receptor agonist LY379268. Neuroscience 2003; 117: 697-706. (Pubitemid 36263162)
34. Moghaddam B, Adams B, Verma A, Daly D. Activation of glutamatergic neurotransmission by ketamine: A novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex. J Neurosci 1997; 17: 2921-2927. (Pubitemid 27155025)
35. Janoshazi A, Deraet M, Callebert J, Setola V, Guenther S, Saubamea B et al. Modified receptor internalization upon coexpression of 5-HT1B receptor and 5-HT2B receptors. Mol Pharmacol 2007; 71: 1463-1474. (Pubitemid 47010899)
36. Alexander B, Warner-Schmidt J, Eriksson T, Tamminga C, Arango-Lievano M, Ghose S et al. Reversal of depressed behaviors in mice by p11 gene therapy in the nucleus accumbens. Sci Transl Med 2010; 2: 54ra76.
37. Machado-Vieira R, Salvadore G, Diazgranados N, Zarate CA Jr. Ketamine and the next generation of antidepressants with a rapid onset of action. Pharmacol Ther 2009; 123: 143-150.
38. Marin P, Becamel C, Dumuis A, Bockaert J. 5-HT receptor-associated protein networks: new targets for drug discovery in psychiatric disorders? Curr Drug Targets 2012; 13: 28-52.
39. Peddie CJ, Davies HA, Colyer FM, Stewart MG, Rodriguez JJ. A subpopulation of serotonin 1B receptors colocalize with the AMPA receptor subunit GluR2 in the hippocampal dentate gyrus. Neurosci Lett 2010; 485: 251-255.
40. Carelli RM. The nucleus accumbens and reward: neurophysiological investigations in behaving animals. Behav Cogn Neurosci Rev 2002; 1: 281-296.
41. Rolls ET, Burton MJ, Mora F. Neurophysiological analysis of brain-stimulation reward in the monkey. Brain Res 1980; 194: 339-357. (Pubitemid 10084612)
42. Epstein J, Pan H, Kocsis JH, Yang Y, Butler T, Chusid J et al. Lack of ventral striatal response to positive stimuli in depressed versus normal subjects. Am J Psychiatry 2006; 163: 1784-1790. (Pubitemid 44522488)
43. Schlaepfer TE, Cohen MX, Frick C, Kosel M, Brodesser D, Axmacher N et al. Deep brain stimulation to reward circuitry alleviates anhedonia in refractory major depression. Neuropsychopharmacology 2008; 33: 368-377. (Pubitemid 350243349)
44. Price JL, Drevets WC. Neurocircuitry of mood disorders. Neuropsychopharmacology 2010; 35: 192-216.
45. Tachibana Y, Hikosaka O. The primate ventral pallidum encodes expected reward value and regulates motor action. Neuron 2012; 76: 826-837.
46. Hu J, Henry S, Gallezot JD, Ropchan J, Neumaier JF, Potenza MN et al. Serotonin 1B receptor imaging in alcohol dependence. Biol Psychiatry 2010; 67: 800-803.
47. Potenza MN, Walderhaug E, Henry S, Gallezot JD, Planeta-Wilson B, Ropchan J et al. Serotonin 1B receptor imaging in pathological gambling. World J Biol Psychiatry 2013; 14: 139-145.
48. Murrough JW, Czermak C, Henry S, Nabulsi N, Gallezot JD, Gueorguieva R et al. The effect of early trauma exposure on serotonin type 1B receptor expression revealed by reduced selective radioligand binding. Arch Gen Psychiatry 2011; 68: 892-900.